Procarbazine Hydrochloride is primarily used in the treatment of Hodgkin's lymphoma, often as part of a combination chemotherapy regimen known as MOPP (mechlorethamine, vincristine, procarbazine, and prednisone). It works by interfering with the DNA and RNA synthesis in cancer cells, thereby inhibiting their growth and proliferation. This drug is particularly effective in targeting rapidly dividing cells, making it a valuable component in cancer therapy. Additionally, it is sometimes used in the treatment of other cancers, such as brain tumors and non-Hodgkin's lymphoma, when other treatments have not been successful. Due to its mechanism of action, it is crucial for patients to be monitored for potential side effects, including bone marrow suppression and increased risk of infections. Proper medical supervision is essential to manage these risks effectively.